ASSIGNMENT AND CONSULTING SERVICE AGREEMENTAssignment and Consulting Service Agreement • November 13th, 2023 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
THIS ASSIGNMENT AND CONSULTING SERVICE AGREEMENT (“Agreement”), dated as of March 30 , 2023 (“Effective Date’’), is entered into by and between Suzhou Aprinoia Therapeutics Co. Ltd., a company duly organized under the laws of People’s Republic of China, having its registered office at R503, 5F, Building B2, 218 Xing Hu Rd., Suzhoulndustrial Park, Suzhou, PRC (“APN SZ”), APRINOIA Therapeutics Inc., a company incorporated under the laws of the Cayman Islands, with its registered office at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (“APN Cayman”), Yantai Yitai Pharmaceutical Technology Co., Ltd., a company duly organized under the laws of the People’s Republic of China, having its registered office at Room 101, Block 52, No. 500, East Bin Hai Rd., Mu Ping District, Yan Tai, Shandong Province, PRC (“Yitai”), and Yantai Dongcheng Pharmaceutical Group Co., Ltd., a company duly organized under the laws of the People’s Republic of China, having its place of business at No
Amendment Number Four AgreementAmendment Agreement • November 13th, 2023 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Amendment Agreement (the “Number Four Agreement”) is entered into as indicated below, among National Institutes for Quantum Science and Technology (“QST”), a research institute in Japan, having an address at 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan, APRINOIA Therapeutics Inc. (“APRINOIA JP”), a corporation of Japan, having an address at Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan and Suzhou APRINOIA Therapeutics Co., Ltd. (“APRINOIA CN”), a corporation of China, having an address at R503, 5F, Building B2, 218 Xing Hu Rd., Suzhou Industrial Park, Suzhou 215213, China, in consideration of the mutual agreement to make alterations to the Exclusive License Agreement (the “Original Agreement”) executed on October 20th, 2016 by QST and APRINOIA TW, the Amendment Agreement (the “Number One Agreement”) executed on January 11th ,2018, the Amendment Number Two Agreement (the “Number Two Agreement”) executed on June 1st ,2019 and the Amendment Number Three Agreement (the “
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • November 13th, 2023 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations • Hong Kong
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (“Agreement”), dated as of March 20, 2023 (“Effective Date”), is entered into by and between APRINOIA Therapeutics Inc., a company duly organized under the laws of Japan, having its place of business at Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan (“APN JP”), APRINOIA Therapeutics Inc., a company incorporated under the laws of the Cayman Islands, with its registered office at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (“APN Cayman”), Yantai Yitai Pharmaceutical Technology Co., Ltd., a company duly organized under the laws of the People’s Republic of China, having its place of business at Room 101, Block 52, No. 500, East Bin Hai Rd., Mu Ping District, Yan Tai, Shandong Province, PRC (“Yitai”), and Yantai Dongcheng Pharmaceutical Group Co., Ltd., a company duly organized under the laws of the People’s Republic of China, having its place of business at No.7, Changbai Mountain Rd., Economic and Technological Development
Exclusive License AgreementExclusive License Agreement • November 13th, 2023 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Exclusive License Agreement (the “Agreement”), dated as of October 20th, 2016, (“Effective Date”) is entered into by and between the National Institutes for Quantum and Radiological Science and Technology (“QST”), a research institute in Japan, having an address at 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan, and APRINOIA Therapeutics Inc. (“APRINOIA”), a corporation of Taiwan, having an address at 17F., No.270, Sec. 4, Zhongxiao E. Rd., Da-an Dist., Taipei City 106, Taiwan (R.O.C.).
Amendment AgreementAmendment Agreement • November 13th, 2023 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Amendment Agreement (the “Agreement”) is entered into as indicated below, among the National Institutes for Quantum and Radiological Science and Technology (“QST”), a research institute in Japan, having an address at 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan, APRINOIA Therapeutics Inc. (“APRINOIA TW”), a corporation of Taiwan, having an address at 17F., No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan (which is migrated from 17F., No.270, Sec. 4, Zhongxiao E. Rd., Da-an Dist., Taipei City 106, Taiwan (R.O.C.) on January 16th, 2017) and APRINOIA Therapeutics Inc. (“APRINOIA KY”), a corporation of Cayman Islands, having an address at The Grand Pavilion Commercial Centre, Oleander Way, 802 West Bay Road, P.O. Box 32052, Grand Cayman KY1-1208, Cayman Islands, in consideration of the mutual agreement to make alterations to the Exclusive License Agreement (the “Original Agreement”) executed on October 20th, 2016 by QST and APRINOIA TW.
Amendment Number Two AgreementAmendment Agreement • November 13th, 2023 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Amendment Agreement (the “Number Two Agreement”) is entered into as indicated below, among National Institutes for Quantum and Radiological Science and Technology (“QST”), a research institute in Japan, having an address at 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan, APRINOIA Therapeutics Inc. (“APRINOIA TW”), a corporation of Taiwan, having an address at 17F., No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan and APRINOIA Therapeutics Inc. (“APRINOIA KY”), a corporation of Cayman Islands, having an address at The Grand Pavilion Commercial Centre, Oleander Way, 802 West Bay Road, P.O. Box 32052, Grand Cayman KY1-1208, Cayman Islands, in consideration of the mutual agreement to make alterations to the Exclusive License Agreement (the “Original Agreement”) executed on October 20th, 2016 by QST and APRINOIA TW and the Amendment Agreement (the “Number One Agreement”) executed on January 11th ,2018 by QST, APRINOIA TW and APRINOIA KY.
Amendment Number Three AgreementAmendment Agreement • November 13th, 2023 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Amendment Agreement (the “Number Three Agreement”) is entered into as indicated below, among National Institutes for Quantum and Radiological Science and Technology (“QST”), a research institute in Japan, having an address at 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan, APRINOIA Therapeutics Inc. (“APRINOIA TW”), a corporation of Taiwan, having an address at 17F., No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan, APRINOIA Therapeutics Inc. (“APRINOIA JP”), a corporation of Japan, having an address at Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan and Suzhou APRINOIA Therapeutics Co., Ltd. (“APRINOIA CN”), a corporation of China, having an address at R503, 5F, Building B2, 218 Xing Hu Rd., Suzhou Industrial Park, Suzhou 215213, China, in consideration of the mutual agreement to make alterations to the Exclusive License Agreement (the “Original Agreement”) executed on October 20th, 2016 by QST and APRINOIA TW, the Amendment Agreement (the “Number One Agreement”
